Piper Sandler Maintains Overweight on Amphastar Pharma, Lowers Price Target to $66
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst David Amsellem maintains an Overweight rating on Amphastar Pharma (NASDAQ:AMPH) but lowers the price target from $71 to $66.
August 08, 2024 | 11:33 am
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Piper Sandler maintains an Overweight rating on Amphastar Pharma but lowers the price target from $71 to $66.
The Overweight rating suggests continued confidence in Amphastar Pharma's performance, but the lowered price target indicates some caution. This mixed signal is likely to result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100